Immune cell treatment for recurrent ATRT brain tumors
Part of Cancer clinical trials.
This trial tests a special type of immune cell treatment (CAR T cells) for a rare brain tumor called ATRT that has come back after standard treatment. The cells are made to find and attack tumor cells that carry a marker called GPC3, which may help reduce or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient must be at least 6 months old.
- The tumor must be a type called ATRT (a rare brain cancer) that has come back or not been removed with standard treatments.
- The tumor must show a protein called GPC3 on its surface (this is checked on a biopsy).
- The patient should be in reasonably good health (able to carry on daily activities – a score of at least 60% on a performance scale).
- The patient must be stable without needing to increase steroids for 7 days before the study, and not on other cancer treatments.
- Organ transplant is not allowed, and active infections (unless hepatitis B or C) must be absent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Hear when a new Atypical Teratoid/Rhabdoid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.